Tiziana Life Sciences (TLSA) has released an update.
Tiziana Life Sciences has secured $3.4 million in non-dilutive funding, bolstering its financial position as it progresses with Phase 2 trials for its novel intranasal therapy foralumab in multiple sclerosis and Alzheimer’s Disease. The company, known for its pioneering nasal drug delivery technology, aims to enhance treatment efficacy and patient safety compared to traditional intravenous methods. This financial infusion will support Tiziana’s ongoing research and development efforts in neurodegenerative disease treatment.
For further insights into TLSA stock, check out TipRanks’ Stock Analysis page.
